Lamivudine
This oral antiretroviral nucleoside analog used to treat HIV is also FDA-approved for treatment of chronic HBV infection. A trial in Asian patients with chronic HBV infection treated for 2 years found that 52% taking lamivudine 100 mg daily had sustained suppression of HBV DNA, 50% had normalization of aminotransferase activity and seroconversion to anti-HBeAg occurred in 27% . In patients with cirrhosis or advanced fibrosis, treatment for up to 42 months reduces the risk of clinical progression and hepatocellular carcinoma development by about half